Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure?
- 1 July 1998
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 136 (1) , 43-48
- https://doi.org/10.1016/s0002-8703(98)70180-2
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?Journal of the American College of Cardiology, 1996
- A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1995
- The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial InfarctionNew England Journal of Medicine, 1995
- Natural history and patterns of current practice in heart failureJournal of the American College of Cardiology, 1993
- The epidemiology of heart failure: The Framingham StudyJournal of the American College of Cardiology, 1993
- Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1992
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992
- A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart FailureNew England Journal of Medicine, 1991
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987